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Abstract
Background: Classic galactosemia is a rare inborn error of carbohydrate metabolism, caused by a severe deficiency
of the enzyme galactose-1-phosphate uridylyltransferase (GALT). A galactose-restricted diet has proven to be very
effective to treat the neonatal life-threatening manifestations and has been the cornerstone of treatment for this
severe disease. However, burdensome complications occur despite a lifelong diet. For rare diseases, a patient
disease specific registry is fundamental to monitor the lifespan pathology and to evaluate the safety and efficacy of
potential therapies. In 2014, the international Galactosemias Network (GalNet) developed a web-based patient
registry for this disease, the GalNet Registry. The aim was to delineate the natural history of classic galactosemia
based on a large dataset of patients.
Methods: Observational data derived from 15 countries and 32 centers including 509 patients were acquired between
December 2014 and July 2018.
Results: Most affected patients experienced neonatal manifestations (79.8%) and despite following a diet developed
brain impairments (85.0%), primary ovarian insufficiency (79.7%) and a diminished bone mineral density (26.5%).
Newborn screening, age at onset of dietary treatment, strictness of the galactose-restricted diet, p.Gln188Arg mutation
and GALT enzyme activity influenced the clinical picture. Detection by newborn screening and commencement of diet
in the first week of life were associated with a more favorable outcome. A homozygous p.Gln188Arg mutation, GALT
enzyme activity of ≤ 1% and strict galactose restriction were associated with a less favorable outcome.
Conclusion: This study describes the natural history of classic galactosemia based on the hitherto largest data set.
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Background
Classic galactosemia (CG, OMIM # 230400) is a rare inborn
error of carbohydrate metabolism, caused by a severe defi-
ciency of the enzyme galactose-1-phosphate uridylyltrans-
ferase (GALT, E.C. 2.7.7.12). GALT is the second enzyme in
the Leloir pathway, the main route of galactose metabolism.
CG has a prevalence in western countries of between
1:16,000 and 1:60,000 live births [1, 2]. At present, over 300
variations in the GALT gene have been identified, with
c.563A>G (p.Gln188Arg) being the most common patho-
genic variation among people of European ancestry [3].
The first description of a neonate with galactosemia
showing acute systemic toxicity was in 1908. In 1935,
the case of an infant with hypergalactosemia and galac-
tosuria who responded well to a lactose-restricted diet at
10 months of age was described [4]. In 1956, GALT was
characterized as the enzyme that is affected in CG [5]
and in 1988 the GALT gene was identified [6]. The
pathophysiology is complex and not fully understood.
Various mechanisms have been implicated [7–16].
CG presents in the neonatal period when upon
exposure to galactose-containing milk, newborns de-
velop feeding difficulties, failure to thrive, hepatocellu-
lar damage, E. coli sepsis, hypotonia, renal tubular
disease and cataracts [13]. Several countries have im-
plemented newborn screening (NBS) for CG. The
current standard of care, a galactose-restricted diet,
resolves the neonatal clinical picture. Unfortunately,
despite diet, most patients develop complications that
affect mainly the central nervous system and the female
gonads, resulting in cognitive, neurological and behav-
ioral complications and primary ovarian insufficiency
(POI) with subsequent subfertility in female patients
[17, 18]. In addition, patients are at risk of a diminished
bone mineral density (BMD) [19, 20]. The clinical
phenotype can vary considerably even in patients har-
boring the same genotype and within the same family.
The scarcity of relevant knowledge and outcome ex-
perience with most rare diseases creates a need for
disease specific patient registries. Rare disease registries
are a tool to gather comprehensive knowledge to im-
prove patient care, to monitor the pathogenesis of a
disorder over a lifespan and to support clinical re-
search, particularly the safety and efficacy evaluation of
potential therapies and treatment strategies [21–23].
The international network for the galactosemias (Gal-
Net) [24] developed and implemented a web-based patient
registry in 2014, the GalNet registry, that includes type I
(classic and variant galactosemia), type II (galactokinase
deficiency) and type III galactosemia (galactose epimerase
deficiency). This study aims to delineate the natural his-
tory of classic galactosemia based on a large data set of
patients. This information is of utmost importance for all
stakeholders involved in the care of this group of patients.
Results
Patients’ characteristics
A total of 509 patients (48.1% male and 51.9% female)
from 15 countries were included; data was collected from
December 2014 to July 2018. The age ranged from 0 to
65 years (median 18.0 years) and the majority of patients
were Caucasian, 93.6% (436/466). Mutational analysis
revealed c.563A >G (p.Gln188Arg) homozygosity as the
most common genotype, in 57.7% (233/404). Because of
the coded character of the data, we have no information
on sibling relationship to elaborate on the number of in-
dependent mutant alleles. Enzyme activity was ≤ 1% in
82.7% (211/255) of patients. Diagnosis was established fol-
lowing a positive newborn screening (NBS) in 45.9%
(215/468) of patients (Table 1).
Neonatal illness
Neonatal illness was reported in 79.8% (332/416) of
patients. The commonest documented abnormalities were
elevated liver enzymes in 70.3% (211/300), bleeding diath-
esis in 42.5% (128/301), encephalopathy in 29.0% (71/245),
clinical signs of infection in 27.4% (96/351), cataract in
Table 1 Patients’ characteristics
n Valid n %
Gender 509
Male 245 48.1
Female 264 51.9
Age (years) 509
< 18 years 233 45.8
≥ 18 years 276 54.2
Ethnicity 466
Caucasian 436 93.6
Othera 30 6.4
GALT gene mutationb 404
c.[563A>G];[563A>G] (p.[(Gln188Arg)];[(Gln188Arg)]) 233 57.7
c.[563A>G];[855G>T] (p.[(Gln188Arg)];[(Lys285Asn)]) 29 7.2
c.[563A>G];[584T>C] (p.[(Gln188Arg)];[(Leu195Pro)]) 10 2.5
c.[563A>G];[5.2 kb del] 5 1.2
c.[855G>T];[855G>T] (p.[(Lys285Asn)];[(Lys285Asn)]) 7 1.7
c.[855G>T];[584T>C] (p.[(Lys285Asn)];[(Leu195Pro)]) 2 0.5
c.[584T>C];[584T>C] (p.[(Leu195Pro)];[(Leu195Pro)]) 3 0.7
c.[5.2 kb del];[5.2 kb del] 3 0.7
Other 112 27.7
Enzyme activity 255
≤ 1% 211 82.7
> 1≤ 5% 36 14.1
> 5≤ 10% 8 3.1
Diagnosed following NBS 215 468 45.9
Median age 18 years, range 0–67 years
aBlack, Mixed, Asian, North African
bFor simplicity reasons, the mutation NM_000155.2(GALT):c.[−1039_753del;820
+ 50_*789delinsGAATAGACCCCA] is here mentioned as 5.2 kb del
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25.8% (68/264) and hypoglycemia in 25.1% (65/259). The
neonatal erythrocyte galactose-1-phosphate (Gal-1-P) peak
level was increased in 90.8% (89/98) of patients (Table 2).
Diagnosis following NBS and early initiation of galactose
restriction within the first week of life were associated with
a lower odds ratio for neonatal complications (p <
0.0000001; OR 0.30 [0.20–0.47] and p < 0.000001; OR 0.32
[0.21–0.50], respectively). Patients diagnosed following the
NBS were often younger (p < 0.000001) and started diet in
the first week of life (p < 0.000000000001). An enzyme ac-
tivity of ≤ 1% was associated with a higher rate of acute
neonatal illness (p = 0.017; OR 2.65 [1.23–5.70]).
Long-term complications
Neurological, cognitive and behavioral complications
Brain impairments were frequently reported, in 85.0%
(277/326) of patients (Table 3, Fig. 1). Global develop-
mental delay was documented in 52.2% (167/320) of the
patients. A great majority in this group, 78.0% (128/164)
of patients, showed also a language delay. Additionally,
isolated language delay was reported for 21.8% (37/170)
of the patients. No gender differences were observed.
Language and speech disorders were often reported, in
66.4% (192/289) of the patients, with speech defect in
41.0% (129/315), impairment in vocabulary in 40.6% (117/
288), impairment in grammar in 38.7% (98/253), verbal
dyspraxia in 23.5% (67/285), and dysarthria in 19.9% (49/
246) of patients. Language and speech disorders were
more often reported in young male patients (p = 0.034).
Analysis of neurological complications data revealed a
prevalence of 52.0% (168/323) in the study population,
with tremor as most frequent complication in 31.0%
(104/336) of the patients. Tremor was more often first
detected after the second decade of life, in 41.3% (26/63)
of patients, but also between pre-school age and the
second decade, in 34.9% (22/63) of patients and between
the first year and pre-school age, in 23.8% (15/63) of pa-
tients. Other neurological complications were general
motor abnormality (clumsiness, coordination difficulties)
in 27.0% (86/319), ataxia in 12.2% (40/329), seizures in
8.1% (26/320) and dystonia in 7.5% (24/318) of patients.
Some patients exhibited a combination of the
above-mentioned neurological complications. In none of
the patients, chorea or athetosis was reported. General
motor abnormality was reported most frequently at
pre-school age, whereas ataxia, seizures and dystonia
manifested at all ages. Male and female patients were
equally affected.
Mental and behavioral problems occurred in 128/288,
44.4% of the patients with a higher frequency in male pa-
tients as they grow older (p = 0.017). The most frequently
reported were anxiety disorder in 22.3% (67/300) of pa-
tients. Other complications included depression, in 12.5%
(38/303), ADHD in 7.3% (21/286) and ASD in 6.0% (17/
281) of patients. The time of onset of mental and behav-
ioral problems varied: depression was mainly seen after
Table 2 Neonatal illness
n Valid n %
Acute neonatal illnessa 332 416 79.8
Elevated liver enzymes (ALT,
AST > 30 U/L)
211 300 70.3
Bleeding diathesis (abnormal
PT/ APTT)
128 301 42.5
Encephalopathyb 71 245 29.0
Signs of infection 96 351 27.4
Positive blood culture 36 64 56.3
Cataract 68 264 25.8
Hypoglycemia (< 2.6 mmol/L) 65 259 25.1
Increased neonatal Gal-1-P
(> 0.05 μmol/g Hb or > 10mg/dL)
89 98 90.8
aDefined as having one of the following symptoms: encephalopathy, bleeding
diathesis, signs of infection, elevated liver enzymes or hypoglycemia
bAltered mental state: depressed consciousness with or without neurological signs
Table 3 Neurological, cognitive and mental (psychiatric)
complications
n Valid n %
Developmental delay infancy/childhood 167 320 52.2
Motor 18 10.8
Cognitive 66 39.5
Motor and cognitive 83 49.7
Language delayb 128 164 78.0
Isolated language delay 37 170 21.8
Language and speech disordersa 192 289 66.4
Speech defect 129 315 41.0
Impairment in vocabulary 117 288 40.6
Impairment in grammar 98 253 38.7
Verbal dyspraxia 67 285 23.5
Dysarthria 49 246 19.9
Neurological complicationsa 168 323 52.0
Tremor 104 336 31.0
General motor abnormality 86 319 27.0
Ataxia 40 329 12.2
Seizures 26 320 8.1
Dystonia 24 318 7.5
Mental (psychiatric) and behavioral problemsa 128 288 44.4
Anxiety disorder 67 300 22.3
Depression 38 303 12.5
ADHD 21 286 7.3
Autism spectrum disorder 17 281 6.0
aDefined as having at least one of the complications in that category,
compared to having none of them
bLanguage delay and motor and/or cognitive developmental delay
Rubio-Gozalbo et al. Orphanet Journal of Rare Diseases           (2019) 14:86 Page 3 of 11
the second decade. Anxiety disorders were common in all
age categories, with 36.8% (14/38) of patients presenting
between pre-school age and the second decade and 55.3%
(21/38) in the second or third decade of life. In 7.9% (3/
38) of patients, anxiety disorders were reported in the
pre-school age. ADHD and ASD were more likely to
occur in early life, before the second decade.
Further analysis revealed that neurological complica-
tions were less prevalent in subjects with age below 18
years (p < 0.00000001; OR 0.15 [0.15–0.39]) and in pa-
tients diagnosed following NBS (p < 0.00001; 0.32
[0.20–0.51]). These patients more often were started on
diet therapy in the first week of life (p < 0.000000000001),
unlike those who were not diagnosed earlier following NBS.
Patients with a strict diet (lactose restricted and restrictions
in fruit and vegetables) developed neurological complica-
tions more frequently (p < 0.001; OR 2.81 [1.64–4.50]) than
patients with a less strict diet.
Mental (psychiatric) and behavioral problems were less
often reported in younger patients (p < 0.001); OR 0.42
[0.26–0.68]). An enzyme activity ≤ 1% was associated with a
higher occurrence of mental and behavioral problems (p =
0.010; OR 3.41 [1.37–8.50]). Patients old enough to be
assessed, more often did not reach a high level of education
[25], 16.4% (29/177) compared to 30.7% (59/192) of the
mothers and 42.7% (82/192) of the fathers
(Additional file 1: Table S1). Patients attended special edu-
cation programs more frequently, in 26.1% (42/161). The
occupation [26] showed that patients perform unskilled
occupations more often, in 45.6% (68/149) compared to
their parents (16.5% (33/200) fathers and 26.8% (56/209)
mothers) (Additional file 2: Table S2).
Gonadal complications
Spontaneous puberty was reported in 51.5% (69/134) of
the female patients whereas 48.5% (65/134) had a delayed/
induced puberty. The median age at spontaneous puberty
was 13 years (range 10 to 17 years). The median age at in-
duction of puberty was 13 (range 9 to 20 years). POI was
reported in 79.7% (118/148) of female patients. In females
aged > 35 years, POI percentage increased to 85.1% (40/
47). In women with POI, 83.5% (86/103) patients reported
to use hormone replacement therapy (HRT), median age
of start of the HRT was 16 years (range 11 to 45 years). In
the studied population, 16.8% (16/95) of female patients
with POI tried to conceive and 25.0% (4/16) of these
women successfully became pregnant without assisted
reproduction. The median age of women when their first
child was born was 25 years (range 17 to 38 years). Further
analysis showed that a homozygous p.Gln188Arg muta-
tion was associated with a higher odds ratio for POI (p =
0.040; OR 2.84 [1.08–7.47]). Delayed puberty in boys was
reported in 4.8% (3/63) of patients. Male patients suffered
from cryptorchidism in 5.6% (3/54) and 7.8% (5/64) had
fathered a child (Table 4, Fig. 2).
Bone health
The median BMD Z-score of the studied population was
− 0.8 SD (range − 5.1 to 4.0 SD), the median T-score was
− 1.1 SD (range − 4 to 4.3 SD). A diminished BMD,
A C
B D
a Defined as having at least one of the complications in that category, compared to having none of them.
* Language delay and motor and/or cognitive developmental delay.
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Isolated language delay 
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Fig. 1 Frequency of neurological, cognitive and mental (psychiatric) complications. a Developmental delay infancy/childhood. b Language and
speech disorders. c Neurological complications. d Mental (psychiatric) and behavioral problems. The n/valid n is shown per outcome
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defined as a BMD T-score ≤ − 1,0 standard deviation (SD)
or a BDM Z-score ≤ − 2,0 SD, was reported in 26.5% (76/
287) of the patients, where 65.8% (50/76) was female
(Additional file 3: Table S3, Fig. 3). Fracture prevalence in
this population was 9.9% (21/213). The median age of the
patients with a fracture was 24 years (range 6 to 59 years).
A low BMD was present in 23.8% (5/21) of the patients
with fractures, 61.1% of patients with a fracture were male.
Vitamin D deficiency (< 50 nmol/L) [27, 28] was docu-
mented in 26.5% (53/200). The majority of patients re-
ceived calcium and vitamin D supplements (68.2% (281/
412) and 71.1% (288/405), respectively). In the vitamin D
deficiency group, 76.1% (35/46) and 80.9% (38/47) of the
patients received calcium and vitamin D supplements, re-
spectively. Physical activity, according to the World Health
Organization (WHO) advice [29], was reported for 75.3%
(140/186) of the patients. In 31/49 (63.3%) of patients
with sufficient physical activity, a low BMD was re-
ported. Patients with a low BMD were taking Vitamin
D and calcium supplements in 94.1% (64/68) and 95.7%
(67/70) respectively.
Cataract
Cataract in the neonatal period was reported in 25.8%
(68/264) of the patients. In 54.5% (24/44) the cataract
disappeared after introduction of diet, whereas in 45.5%
(20/44) of patients a residual cataract was documented. A
minority of patients developed cataract after the neonatal
period, 9.2% (22/238). There was another group of
patients, 11.2% (10/89), in whom cataract was re-
ported in adulthood (median 29.5 years, range 18 to 41
years) (Additional file 4: Table S4). No information on gross
deviations from diet or other reasons for cataract is available.
Diet
During the neonatal period, most of the children were
given a soy infant formula 76.6% (302/394). A minority,
12.7% (50/394), received elemental formula and the re-
mainder had other galactose-restricted formulas, 10.7%
(42/394). Diet was implemented within the first day of
life in 16.6% (65/391) of the patients, whereas 33.9%
(133/391) of the patients started diet on the remaining
days of the first week of life. In 34.2% (134/391) of the
cases diet was implemented in the second week, in
9.4% (37/391) in the third and fourth week, and in 5.9%
(23/391) after more than 28 days. After the neonatal
period, most of the patients followed a lactose-free diet,
94.2% (406/431). The majority of patients adhered to a
relaxed diet (lactose free without further restrictions),
in 64.3% (245/381) rather than a strict diet (lactose free
and restriction of non-dairy sources) in 35.7% (136/
381) (Additional file 5: Table S5).
Discussion
The aim of this descriptive study was to delineate the
natural history of patients with a residual GALT activity
of ≤10% and/or GALT severe disease-causing mutations
based on the largest cohort studied so far (n = 509) from
many countries with different genetic backgrounds. Our
data confirm that most patients experience neonatal ill-
ness, and that despite the diet, they develop brain and
gonadal impairments and are at risk for a lower BMD.
Neonatal illness
This analysis in a large study population is in agreement
with earlier descriptions of frequent occurrence of liver
damage with bleeding diathesis, and infection in the
neonatal period [17, 30]. A reported lower enzyme activ-
ity was related to a higher rate of neonatal illness. Diag-
nosis through NBS was associated with a more favorable
neonatal presentation. These patients were younger at
diagnosis and diet was more often introduced in the first
week of life. The positive effect of early dietary treatment
A B
1 Diagnosed in women below the age of 40 years, with at least 40 months of amenorrhea and 2 independent, more than 1-month apart, FSH levels in the 
menopausal state. 
* In women with primary ovarian insufficiency.
** Of women with primary ovarian insufficiency who tried to conceive.
*** A delayed puberty was defined as a lack of increase in testicle size by age 14.
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Fig. 2 Frequency of gonadal complications. a Gonadal complications in female patients. b Gonadal complications in male patients. The n/valid n is
shown per outcome
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on neonatal complications has been known for a long
time [31, 32] and these results corroborate this finding.
Neurological, cognitive and behavioral complications
There is a high occurrence of brain impairments, includ-
ing developmental and language delay, neurological
complications, language and speech disorders and men-
tal and behavioral problems. The most frequently seen
neurological symptom was tremor, in 31.0% (104/336)
with a lower occurrence than in previous reports with
smaller cohorts [30, 33]. The prevalence of other neuro-
logical symptoms (general motor abnormality ataxia, sei-
zures and dystonia) was in line with earlier findings [30,
33]. In this large dataset, we were able to also assess the
time of onset of the complications. Tremor was more
often seen after the second decade of life, but also be-
tween the first year and pre-school age and between
pre-school age and the second decade.
Importantly, the occurrence of mental and behavioral
problems was not different from the general population.
The most frequently reported were anxiety disorder and
general behavioral problems. Other complications in-
cluded depression, ADHD and ASD. Behavioral problems
were more likely to occur before the second decade,
whereas mental (psychiatric) problems, such as depression
and anxiety disorder were more predominant after the
second decade. Anxiety disorders were common in all age
categories. In previous reports, based on smaller patient
cohorts, the occurrence of anxiety disorders in adults was
reported to be higher [30, 33]. This difference could be
due to the age distribution in our data set.
Interestingly, patients with a relaxed diet (lactose free
without further restrictions) less often developed neuro-
logical complications. Previous studies suggested that a
more relaxed diet did not seem to be associated with a
more severe clinical outcome [2, 34–36]. A recent study
in a large patient cohort (n = 231) reported that the rigor
of non-dairy galactose restriction in early childhood does
not associate with severity of long-term outcomes
growth, adaptive behaviors, receipt of speech therapy, re-
ceipt of educational services and ovarian function [37].
Moderate liberalization of galactose intake (suggested
due to galactose’s importance for glycosylation of glyco-
proteins and glycolipids) has been shown to improve
IgG glycosylation in a small subset of pediatric and adult
patients [38, 39]. It is possible like other inborn errors of
metabolism requiring substrate precursors that a mini-
mum amount of exogenous dietary galactose is neces-
sary for all CG patients. Our results support the
1  65.8 % was female.
2 Median age of patients who reported fractures was 24 years, range 6 to 59 years. 61.1% of patients with a fracture 
was male.
3 The World Health Organization (WHO) recommends 60 minutes of moderate- to vigorous-intensity physical activity 
per day for children and 150 minutes per week for adults. 
* 76.1% (35/46) and 80.9% (38/47) of the patients with vitamin D deficiency received calcium and vitamin D 
supplements, respectively.  
BMD was measured by dual energy x-ray photometry (DXA) using T- or Z-scores of the lumbar spine, depending 
on age and gender. T-scores were used in post- -scores, considering 
age, gender, and ethnicity, were used in pre-menopausal women and men < 50 years. A low BMD was classified 
as BMD T- -1.0 standard deviation (SD) or a BDM Z- -2.0 SD.
Median BMD Z-score in studied population was -0.8 SD, range -5.1 to 4.0 SD
Median BMD T-score in studied population was -1.1 SD, range -4.0 to 4.3 SD
0 20 40 60 80 100
Adequate physical activity3
Vitamin D supplements*
Calcium supplements* 
Vitamin D deficiency
Vitamin D insufficiency 
Normal Vitamin D level
Fractures2 
Low BMD1
%
76/287
21/213
70/200
288/405
140/186
77/200
281/412
53/200
Fig. 3 Frequency of outcomes in bone health. The n/valid n is shown per outcome
Table 4 Gonadal complications
n Valid n %
Female
Puberty 134
Spontaneous puberty 69 51.5
Induced puberty 65 48.5
Primary ovarian insufficiencya 118 148 79.7
Hormone replacement therapy 86 103 83.5
Tried to conceive 16 95 16.8
Successful pregnancyb 4 16 25.0
Male
Delayed Pubertyc 3 63 4.8
Cryptorchidism 3 54 5.6
Fathered children 5 64 7.8
aDiagnosed in women below the age of 40 years, with at least 40 months of
amenorrhea and 2 independent, more than 1-month apart, FSH levels in the
menopausal state
bOf women who tried to conceive
cA delayed puberty was defined as a lack of increase in testicle size by age 14
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moderate liberalization of diet that is recommended
nowadays [40–42].
Gonadal complications
Ovarian damage was reported in a vast majority of female
patients. Hypergonadotropic hypogonadism in women
with CG was first described in 1979 [18]. Subsequently,
POI was broadly recognized and represents a very burden-
some complication for the patients and their families. The
occurrence of POI in this study was comparable to previ-
ous figures [17, 30, 43, 44]. A high percentage of women
with POI was taking HRT to supplement hormonal insuf-
ficiency, reflecting an appropriate follow-up.
In a previous study by van Erven et al. (2017), 29.6%
of the patients tried to conceive, and successful preg-
nancy was achieved in 42.9% [20]. Our findings reiterate
the need for adjustment in counseling of these women
regarding fertility and reproduction. In the past, fertility
counseling has been discouraging and many women
abandoned trying to conceive. This data strengthens the
notion that, in reproduction counseling subfertility rather
than infertility should be acknowledged which carries im-
plications for the patients when considering fertility pres-
ervation and family planning including contraception if
pregnancy is not desired.
In male subjects, the prevalence of cryptorchidism in
this larger study is less than what was previously described
[45, 46], but still higher than in the general population
(1.0%). Pubertal delay in males is not different compared
to the general population [47]. This is in line with male
gonads not being clinically significantly affected. Only a
small percentage of male patients fathered a child. This
could possibly be explained by the social difficulties [34]
and/or delayed psychosexual and social development in
young adult men with galactosemia [48].
Bone health
A reduced BMD was first described in 1993 [19]. There-
after, several studies confirmed this feature in patients
with CG [30, 49–52]. Hitherto, it is not clear whether
this is secondary to the restricted diet, a primary intrin-
sic disease effect or a combination of both. In this co-
hort we also found reduced BMD in accordance with
previous studies. The majority of patients received vita-
min D and calcium supplementation to meet daily rec-
ommended requirements. Patients with a low BMD were
mostly taking these supplements, but despite the supple-
mentation BMD was still lower. These findings are in line
with the experience in treating these patients, BMD might
improve but not normalize when given supplements. The
number of fractures in this cohort was not higher than in
the general population [53]. It should be noted, however,
that the median age in this cohort was relatively young.
Predictive factors
The development of long-term complications seems to be
associated with NBS, age at onset of dietary treatment,
strictness of the galactose-restricted diet, GALT enzyme
activity and genotype. We found that use of NBS was as-
sociated with a lower rate of neurological symptoms. Since
2005, several countries have implemented NBS for CG.
One exception is Ireland, where they perform an NBS for
galactosemia since 1972 because of the high prevalence
[2]. Evaluation of the effectiveness of NBS in the
Netherlands showed a benefit of NBS in preventing crit-
ical illness [54]. Our data support this concept and can be
taken into consideration by decision-makers for imple-
mentation of NBS for CG in national programs. Enzyme
activity ≤ 1% was associated with more mental and behav-
ioral problems. Homozygosity for p.Gln188Arg and a
strict diet were both associated with a higher rate of
neurological complications and POI. Peak neonatal
erythrocyte Gal-1-P level showed no correlation with any
individual outcome measures. Mean erythrocyte Gal-1-P
was not recorded in our registry. In many centers this par-
ameter is not used for the regular follow-up once an indi-
vidual baseline has been established.
Study limitations
Although a large cohort has been studied, there are limi-
tations to be considered. First, this is a retrospective ob-
servational study and not all patients had been followed
in a standardized systematic manner, in contrast with
the cohort study by Waisbren et al. [30], where patients
received a standardized evaluation, e.g. examination by a
neurologist, endocrine testing and psychological evaluation.
In this registry study, not all patients had received a neuro-
logical evaluation by a neurologist, and the assessment of
tremor, ataxia, dystonia e.g. might not be fully accurate.
Furthermore, the whole age range is included with median
of 18 years (range 0–65 years), implying that for several var-
iables (e.g. POI) data could not be available. All patient data
derived from medical history files, and not all data was
complete and available for collection. This led to limitations
in analyzing possible associations between several factors
and the outcomes. Nevertheless, the registry is still open,
and we expect more data entry from numerous other cen-
ters in the upcoming years to allow multivariate analysis.
Conclusions
In summary, this study provides a description of the nat-
ural history of classic galactosemia based on a large data
set. This study confirms that most affected patients ex-
perience neonatal illness, 79.8% (332/416) and, despite
the diet, develop brain impairments in 85.0% (277/316),
POI in 79.7% (118/148) and a lower BMD in 26.5% (76/
287). NBS, age at onset of dietary treatment, strictness
of the galactose-restricted diet, and GALT enzyme
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activity influence the clinical picture. Onset of diet in
the first week, and diagnosis with NBS are related to a
more favorable outcome. A strict diet, a GALT enzyme
activity ≤ 1% and homozygosity for p.Gln188Arg were
associated with a less favorable outcome.
Patients and methods
GalNet registry
In 2012, the international network for the galactosemias
(GalNet) was established [24]. The GalNet has developed
and implemented an international web-based patient regis-
try, which currently includes centers from several European
countries, Israel and the United States (Additional file 6:
Table S6 and Additional file 7: Table S7, participating cen-
ters and countries). It was established in accordance with
Good Clinical Practice and is in compliance with General
Data Protection Regulation. Data was collected from med-
ical files and coded before entered on the encrypted pass-
word protected registry. Only the principal investigator (PI)
had access to the encrypted code corresponding to the spe-
cific patient. The registry contains information on patients
with any type of galactosemia: classic galactose-1-phosphate
uridylyltransferase deficiency (GALT deficiency, OMIM
#230400), galactokinase deficiency (GALK1, OMIM
#230200) and UDP-galactose-4-epimerase deficiency
(GALE, OMIM #230350). The coordinating center (Maas-
tricht University Medical Center+ (MUMC+)) has devel-
oped the registry, adapted from a Harvard University-based
RedCap system (https://ecrf.ctcm.nl/macro/). The MACRO
software is used, installed and configured according to the
Elsevier manual on a server of the MUMC+ (https://www.
elsevier.com/about/policies/privacy-principles/gdpr). The
study was approved by the local ethics committee of the co-
ordinating center, application number METC 13–4-121.6/
ab, and subsequently approved by participating partners. PIs
from contributing centers submitted the registry proposal to
their local institutions for ethical approval according to na-
tional laws and regulations. A letter of agreement was signed
by participating centers for the use of data. Following ap-
proval, training was provided to the responsible PIs by the
coordinating center. This training included explanation
on the content of the electronic case report (eCRFs)
and how to enter data. Participants were approached by
their treating physicians to participate in the registry
and written consent was obtained from all patients or
their authorized representatives prior to data entry.
Data curation by the coordinating center was per-
formed regularly. Overviews of missing data were pro-
vided, and PIs were contacted to complete datasets.
Inclusion and exclusion criteria
Data derived from 15 countries and 32 centers, were ac-
quired between December 2014 and July 2018. For this
study, only patients with confirmed classic and variant
galactosemia (diagnosed by a residual GALT activity of
≤10% and/or GALT pathogenic disease-causing muta-
tions) were included for analysis. Patients with GALK1
or GALE deficiency were not included. The total num-
ber of patients included for this analysis was 509 (Add-
itional file 6: Table S6 and Additional file 7: Table S7,
participating centers and countries).
Content GalNet registry
Data entry was based on an eCRF using a set of agreed
parameters developed by the GalNet experts. A Har-
vard University-based RedCap system was used to
generate a comprehensive platform to electronically
capture data information on subjects with one of the
galactosemias. This system was shared and adjusted at
the MUMC+ with input from European experts to de-
velop an ease of use system that could be used around
the world. The registry consists of seven eCRFs (1.
Demographics; 2. Neonatal information; 3. General
follow-up; 4. Brain follow-up; 5. Gonads and
reproduction follow-up; 6. Bone health follow-up; 7.
Diet) and contains a user’s manual with explanations
on the different variables (Additional file 8).
Statistical analysis
Data for analysis was exported from the original database
in MACRO to SPSS (IBM SPSS Statistics version 23). Pa-
tient data included in the registry prior to the 31st of July
2018 were included in the analysis. Descriptive analysis
showed medians and ranges for continuous variables and
frequencies and percentages for categorical variables. Dif-
ferences between groups were analyzed using Fisher’s
exact test for categorical variables. All clinical outcomes
have been classified in two categorical groups (presence
vs. absence of outcome) to assess the association of a cer-
tain variable (present vs. absent) with a clinical outcome,
using a Fisher’s exact test for categorical variables. Odds
ratios and 95% confidence intervals with p values are pre-
sented. Logistic regression was performed if the total
number of samples was sufficient. A p value < 0.05 is con-
sidered statistically significant. Our analysis accounted for
missing data due to difficulties in retrieving historical data.
In addition, for some patients some variables were not yet
known due to a young age. When the number of missing
data is > 10%, as is the case for this registry, the results of
subsequent statistical analyses may be biased [55]. Patterns
of missing variables were traceable or predictable from
other variables in the dataset. Methods to handle the miss-
ing observations included performing available case analysis
(for the descriptive analysis) and complete case analysis (for
associations analysis, odds ratios and Fisher’s exact test).
The number of available data per variable is called the valid
number. Valid numbers are shown in the text, Tables 1, 2, 3
and 4, as n/valid n.
Rubio-Gozalbo et al. Orphanet Journal of Rare Diseases           (2019) 14:86 Page 8 of 11
Additional files
Additional file 1: Table S1. International Standard Classification of
Education (ISCED). ISCED 0 Early childhood education; ISCED 1 Primary
education; ISCED 2 Lower secondary education; ISCED 3 Upper secondary
education; ISCED 4 Post-secondary non-tertiary education; ISCED 5
Short-cycle tertiary education; ISCED 6 Bachelor’s or equivalent level;
ISCED 7 Master’s or equivalent level; ISCED 8 Doctoral or equivalent level.
*Included patients have all completed education. **82.9% of the siblings
are still in education. (PDF 173 kb)
Additional file 2: Table S2. Social or occupational classification: Registrar
General’s Social Class (RGSC). (PDF 71 kb)
Additional file 3: Table S3. Bone health. BMD was measured by dual
energy x-ray photometry (DXA) using T- or Z-scores of the lumbar spine,
depending on age and gender. T-scores were used in post-menopausal
women and men ≥ 50 years. Z-scores, considering age, gender, and
ethnicity, were used in pre-menopausal women and men < 50 years.
A low BMD was classified as BMD T-score ≤- 1.0 standard deviation
(SD) or a BDM Z-score ≤- 2.0 SD. Median BMD Z-score in studied
population was - 0.8 SD, range - 5.1 to 4.0 SD. Median BMD T-score in
studied population was - 1.1 SD, range - 4.0 to 4.3 SD. 1 65.8% was fe-
male. 2Median age of patients who reported fractures was 24 years,
range 6 to 59 years. A low BMD was present in 23.8% (5/21) of the
patients with fractures, 61.1% of patients with a fracture was male.
3The World Health Organization (WHO) recommends 60 minutes of moder-
ate- to vigorous-intensity physical activity per day for children and 150 mi-
nutes per week for adults. (PDF 71 kb)
Additional file 4: Table S4. Growth and cataracts. *Median 29.5 years,
range 18 to 41 years. (PDF 54 kb)
Additional file 5: Table S5. Dietary treatment. *We have no information
on siblings’ relations. 1A strict diet was defined as lactose free and restriction
of non-dairy sources (at least one of the following: galactosides, fruit
and vegetables and/or nucleoproteins), with an estimated intake of
galactose < 20 mg/day. 2A relaxed diet was defined as lactose free
without further restrictions with an estimated galactose intake <100
mg/day. (PDF 73 kb)
Additional file 6: Table S6. Participating countries and respective
center(s). Total number of included patients for analysis: 509. (PDF 241 kb)
Additional file 7: Table S7. Participating countries. Total number of
included patients for analysis: 509. (PDF 51 kb)
Additional file 8: Electronic Case Report Forms (eCRFs). (PDF 344 kb)
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